Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

S. D. Smith, B. J. Bolwell, L. A. Rybicki, S. Brown, R. Dean, M. Kalaycio, R. Sobecks, S. Andresen, E. D. Hsi, B. Pohlman, J. W. Sweetenham

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.

Original languageEnglish (US)
Pages (from-to)239-243
Number of pages5
JournalBone Marrow Transplantation
Volume40
Issue number3
DOIs
StatePublished - Aug 1 2007
Externally publishedYes

Fingerprint

Peripheral T-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Anaplastic Large-Cell Lymphoma
Busulfan
Survival
T-Cell Lymphoma
Etoposide
Cyclophosphamide
Stem Cells
Survival Rate
Retrospective Studies
Transplants
Recurrence
Drug Therapy
Therapeutics

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. / Smith, S. D.; Bolwell, B. J.; Rybicki, L. A.; Brown, S.; Dean, R.; Kalaycio, M.; Sobecks, R.; Andresen, S.; Hsi, E. D.; Pohlman, B.; Sweetenham, J. W.

In: Bone Marrow Transplantation, Vol. 40, No. 3, 01.08.2007, p. 239-243.

Research output: Contribution to journalArticle

Smith, SD, Bolwell, BJ, Rybicki, LA, Brown, S, Dean, R, Kalaycio, M, Sobecks, R, Andresen, S, Hsi, ED, Pohlman, B & Sweetenham, JW 2007, 'Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen', Bone Marrow Transplantation, vol. 40, no. 3, pp. 239-243. https://doi.org/10.1038/sj.bmt.1705712
Smith, S. D. ; Bolwell, B. J. ; Rybicki, L. A. ; Brown, S. ; Dean, R. ; Kalaycio, M. ; Sobecks, R. ; Andresen, S. ; Hsi, E. D. ; Pohlman, B. ; Sweetenham, J. W. / Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen. In: Bone Marrow Transplantation. 2007 ; Vol. 40, No. 3. pp. 239-243.
@article{b63caaff017546b2ad406cdfb3893e5d,
title = "Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen",
abstract = "The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18{\%}, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.",
author = "Smith, {S. D.} and Bolwell, {B. J.} and Rybicki, {L. A.} and S. Brown and R. Dean and M. Kalaycio and R. Sobecks and S. Andresen and Hsi, {E. D.} and B. Pohlman and Sweetenham, {J. W.}",
year = "2007",
month = "8",
day = "1",
doi = "10.1038/sj.bmt.1705712",
language = "English (US)",
volume = "40",
pages = "239--243",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

AU - Smith, S. D.

AU - Bolwell, B. J.

AU - Rybicki, L. A.

AU - Brown, S.

AU - Dean, R.

AU - Kalaycio, M.

AU - Sobecks, R.

AU - Andresen, S.

AU - Hsi, E. D.

AU - Pohlman, B.

AU - Sweetenham, J. W.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.

AB - The role of high-dose therapy and autologous stem cell transplantation (ASCT) for patients with peripheral T-cell lymphoma (PTCL) is poorly defined. Comparisons of outcomes between PTCL and B-cell non-Hodgkin's lymphoma (NHL) have yielded conflicting results, in part due to the rarity and heterogeneity of PTCL. Some retrospective studies have found comparable survival rates for patients with T- and B-cell NHL. In this study, we report our single-center experience of ASCT over one decade using a uniform chemotherapy-only high-dose regimen. Thirty-two patients with PTCL-unspecified (PTCL-u; 11 patients) and anaplastic large-cell lymphoma (21 patients) underwent autologous stem cell transplant, mostly for relapsed or refractory disease. The preparative regimen consisted of busulfan, etoposide and cyclophosphamide. Kaplan-Meier 5-year overall survival (OS) and relapse-free survival (RFS) are 34 and 18%, respectively. These results suggest a poor outcome for patients with PTCL after ASCT, and new therapies for T-cell lymphoma are needed.

UR - http://www.scopus.com/inward/record.url?scp=34547169451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547169451&partnerID=8YFLogxK

U2 - 10.1038/sj.bmt.1705712

DO - 10.1038/sj.bmt.1705712

M3 - Article

C2 - 17530000

AN - SCOPUS:34547169451

VL - 40

SP - 239

EP - 243

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 3

ER -